Solid state characterization of olanzapine polymorphs using vibrational spectroscopy

International Journal of Pharmaceutics

Volumn 326, Issue 1-2, 2006, Pages 69-79

  Ayala, A P ^a,b   Siesler, H W ^a   Boese, R ^a   Hoffmann, G G ^a   Polla, G I ^c   Vega, D R ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^c DEPARTAMENTO DE FÍSICA   (Argentina)

Author keywords

Ab initio; DFT; Hydrogen bonding; Infrared spectroscopy; Olanzapine; Polymorphism; Raman spectroscopy

Indexed keywords

OLANZAPINE;

AB INITIO CALCULATION; ARTICLE; CRYSTAL STRUCTURE; DENSITY FUNCTIONAL THEORY; DRUG CONFORMATION; HYDROGEN BOND; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SOLID STATE; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CRYSTALLIZATION; ELECTRONICS; HYDROGEN BONDING; MODELS, CHEMICAL; MODELS, MOLECULAR; MODELS, THEORETICAL; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; SPECTROPHOTOMETRY, INFRARED; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS; SPECTRUM ANALYSIS, RAMAN; VIBRATION;

EID: 33750449634     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.07.023     Document Type: Article

References (38)

1. Becke A.D. Density-functional thermochemistry. 3. The role of exact exchange. J. Chem. Phys. 98 (1993) 5648-5652
2. Bhana N., Foster R.H., Olney R., and Plosker G.L. Olanzapine-an updated review of its use in the management of schizophrenia. Drugs 61 (2001) 111-161
3. Bhana N., and Perry C.M. Olanzapine-a review of its use in the treatment of bipolar I disorder. CNS Drugs 15 (2001) 871-904
4. Bitter I., Dossenbach M.R.K., Brook S., Feldman P.D., Metcalfe S., Gagiano C.A., Furedi J., Bartko G., Janka Z., Banki C.M., Kovacs G., and Breier A. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 (2004) 173-180
5. Blanco M., Coello J., Iturriaga H., Maspoch S., and Perez-Maseda C. Determination of polymorphic purity by near infrared spectrometry. Anal. Chim. Acta 407 (2000) 247-254
6. Boys S.F., and Bernardi F. Calculation of small molecular interactions by differences of separate total energies-some procedures with reduced errors. Mol. Phys. 19 (1970) 553
7. Bunnell, C.A., Hendriksen, B.A., Larsen, S.D., 1996a. Crystal Forms of a Thieno (2,3-b) (1,5)Benzodiazepine Derivative and Process for their Preparation. Eli Lilly and Company, USA and Lilly Industries Ltd., England (EP Patent No. 733635).
8. Bunnell, C.A., Hendriksen, B.A., Larsen, S.D., 1996b. Process and Crystal Forms of 2-Methyl-thieno-benzodiazepine. Eli Lilly and Company, USA and Lilly Industries Ltd., England (WO Patent No. 9630375).
9. Bunnell, C.A., Hotten, T.M., Larsen, S.D., Tupper, D.E., 1997. Process and Solvate of 2-Methyl-thieno-benzodiazepine. Eli Lilly and Company, USA and Lilly Industries Ltd., England (US Patent No. 5631250).
10. Burger A., and Ramberger R. On the polymorphism of pharmaceuticals and other molecular crystals. I. Theory of thermodynamic rules. Mikrochim. Acta II (1979) 259-271
11. Burger A., and Ramberger R. On the polymorphism of pharmaceuticals and other molecular crystals. II. Applicability of thermodynamic rules. Mikrochim. Acta II (1979) 273-316
12. Callaghan J.T., Bergstrom R.F., Ptak L.R., and Beasley C.M. Olanzapine-pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37 (1999) 177-193
13. Campiani G., Butini S., Fattorusso C., Catalanotti B., Gemma S., Nacci V., Morelli E., Cagnotto A., Mereghetti I., Mennini T., Carli M., Minetti P., Di Cesare M.A., Mastroianni D., Scafetta N., Galletti B., Stasi M.A., Castorina M., Pacifici L., Vertechy M., Di Serio S., Ghirardi O., Tinti O., and Carminati P. Pyrrolo [1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J. Med. Chem. 47 (2004) 143-157
14. Campiani G., Butini S., Trotta F., Gemma S., Nacci V., Fiorini I., Fattorusso C., Catalanotti B., Cagnotto A., Mereghetti I., Mennini T., Minetti P., Di Cesare M.A., Stasi M.A., Di Serio S., Ghirardi O., Tinti O., and Carminati P. Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. J. Med. Chem. 48 (2005) 1705-1708
15. Capuano, B., Crosby, I.T., Fallon, G.D., Lloyd, E.J., Yuriev, E., Egan, S.J., 2003. 2-Methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b] [1,5]benzodiazepine methanol solvate monohydrate. Acta Crystallogr. Sect. E: Struct. Rep. Online 59, O1367-O1369.
16. Crupi V., Majolino D., Mondello M.R., Migliardo P., and Venuti V. FT-IR spectroscopy: a powerful tool in pharmacology. J. Pharm. Biomed. Anal. 29 (2002) 1149-1152
17. Fevotte G., Calas J., Puel F., and Hoff C. Applications of NIR spectroscopy to monitoring and analyzing the solid state during industrial crystallization processes. Int. J. Pharm. 273 (2004) 159-169
18. Fini G. Applications of Raman spectroscopy to pharmacy. J. Raman Spectrosc. 35 (2004) 335-337
19. Fogarasi G., Zhou X., Taylor P.W., and Pulay P. The calculation of ab initio molecular geometries: efficient optimization by natural internal coordinates and empirical correction by offset forces. J. Am. Chem. Soc. 114 (1992) 8191-8202
20. Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Cheeseman, J.R., Montgomery Jr., Vreven, T., Burant, J.C., Millam, J.M., Iyengar, S.S., Tomasi, J., Mennucci, B., Cossi, M., Scalmani, G., Rega, N., Nakatsuji, H., Hada, M., Ehara, M., Toyota, K., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Klene, M., Li, X., Knox, J.E., Hratchian, H.P., Cross, J.B., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R.E., Austin, A.J., Cammi, R., Pomelli, C., Ochterski, J.W., Morokuma, K., Voth, G.A., Salvador, P., Nnenberg, J.J., Dapprich, S., Daniels, A.D., Strain, M.C., Malick, D.K., Rabuck, A.D., Raghavachari, K., Ortiz, J.V., Cui, Q., Baboul, A.G., Clifford, S., Stefanov, B.B., Liu, G., Liashenko, A., Piskorz, P., Martin, R.L., Fox, D.J., Keith, T., Al-Laham, M.A., Nanayakkara, A., Challacombe, M., Gill, M.W., Chen, W., Wong, M.W., Gonzalez, C., Pople, J.A., Gaussian 03, Revision C.02. 2003.
21. Fulton B., and Goa K.L. Olanzapine-A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53 (1997) 281-298
22. Grunenberg A., Henck J.O., and Siesler H.W. Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances. Int. J. Pharm. 129 (1996) 147-158
23. Kelleher J.P., Centorrino F., Albert M.J., and Baldessarini R.J. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs 16 (2002) 249-261
24. Lee C.T., Yang W.T., and Parr R.G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron-density. Phys. Rev. B 37 (1988) 785-789
25. Masamura M. The effect of basis set superposition error on the convergence of interaction energies. Theor. Chem. Acc. 106 (2001) 301-313
26. Martin, J.M.L., Van Alsenoy, C., 1995. Gar2ped. University of Antwerp.
27. Parr R.G., and Yang W. Density Functional Theory of Atoms and Molecules (1989), Oxford University Press, New York
28. Petersson G.A., and Allaham M.A. A complete basis set model chemistry. 2. Open-shell systems and the total energies of the 1st-row atoms. J. Chem. Phys. 94 (1991) 6081-6090
29. Petersson G.A., Bennett A., Tensfeldt T.G., Allaham M.A., Shirley W.A., and Mantzaris J. A complete basis set model chemistry. 1. The total energies of closed-shell atoms and hydrides of the 1st-row elements. J. Chem. Phys. 89 (1988) 2193-2218
30. Polla G.I., Vega D.R., Lanza H., Tombari D.G., Baggio R., Ayala A.P., Filho J.M., Fernandez D., Leyva G., and Dartayet G. Thermal behaviour and stability in olanzapine. Int. J. Pharm. 301 (2005) 33-40
31. Pulay P., Fogarasi G., Pang F., and Boggs J.E. Systematic ab initio gradient calculation of molecular geometries, force constants, and dipole moment derivatives. J. Am. Chem. Soc. 101 (1979) 2550-2560
32. Reutzel-Edens S.M., Bush J.K., Magee P.A., Stephenson G.A., and Byrn S.R. Anhydrates and hydrates of olanzapine: crystallization, solid-state characterization, and structural relationships. Cryst. Growth Design 3 (2003) 897-907
33. Varsanyi G. Vibrational Spectra of Benzene Derivatives (1969), Academic Press, New York
34. Vieta E., and Goikolea J.M. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 7 (2005) 21-33
35. Wawrzycka-Gorczyca, I., Koziol, A.E., Glice, M., Cybulski, J., 2004. Polymorphic form II of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b] [1, 5]benzodiazepine. Acta Crystallogr. Sect. E: Struct. Rep. Online 60, O66-O68.
36. Wawrzycka-Gorczyca, I., Mazur, L., Koziol, A.E., 2004. 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine methanol solvate. Acta Crystallogr. Sect. E: Struct. Rep. Online 60, O69-O71.
37. Worrel J.A., Marken P.A., Ruehter V.L., and Beckman S.E. Atypical antipsychotic agents: a critical review. Am. J. Health-Syst. Pharm. 57 (2000) 238-258
38. Zhurko, G.A., Zhurko, D.A., 2005. ChemCraft Tool for Treatment of the Chemical Data. Available from: http://www.chemcraftprog.com.